A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs TAK 041 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 06 Sep 2019 Planned End Date changed from 21 Nov 2019 to 6 Nov 2019.
- 15 Aug 2019 Planned End Date changed from 31 Oct 2019 to 21 Nov 2019.